Methods of treating retinal diseases
AssigneeCell Cure Neurosciences Ltd.
InventorsEyal Banin, Benjamin Eithan Reubinoff, Osnat Bohana-Kashtan, Nir Netzer, Charles Sherard Irving
Life of this patent
Estimating the term…
Abstract
A method of treating a subject with dry-form age-related macular degeneration (AMD) is disclosed. The method comprises administering into the subretina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human RPE cells, wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms to the subject, thereby treating the subject.
Claims31
A method of treating a subject with dry-form age-related macular degeneration (AMD) comprising:
- administering into the subretina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human retinal pigment epithelium (RPE) cells,
- wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms to the subject, thereby treating the subject.
A method of treating a subject with a retinal disease or condition comprising:
- administering into the retina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human polygonal retinal pigment epithelium (RPE) cells,
- wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms to the subject, wherein the therapeutically effective amount is between 50,000-5,000,000 cells per administration, thereby treating the subject.
A method of treating a subject with a retinal disease or condition comprising:
- administering into the retina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human retinal pigment epithelium (RPE) cells using a device,
- wherein the outer diameter of the device through which the cells are administered is between 90-100 μm, thereby treating the subject.
(canceled)
7-9. (canceled)
11-14. (canceled)
(canceled)
19-24. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
41-44. (canceled)
Dependencies are inferred from the claim text.